glyburide and Body Weight studies

Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.

Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.

Research Excerpts

Excerpt	Relevance	Reference
"Our study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with Type 2 diabetes in routine outpatient practice."	9.10	Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. ( Beuth, J; Kolb, H; Martin, S; Scherbaum, WA; Schneider, B; van Leendert, R, 2003)
"Two-stage rat hepatocarcinogenesis model was used to induce early carcinogenesis in which thioacetamide (TAA) promotes diethylnitrosamine (DEN) initiated carcinogenesis."	7.96	Diethylnitrosamine and thioacetamide-induced hepatic damage and early carcinogenesis in rats: Role of Nrf2 activator dimethyl fumarate and NLRP3 inhibitor glibenclamide. ( Dwivedi, DK; Jena, GB, 2020)
"Glyburide did not increase basal or insulin-stimulated DNA synthesis."	5.30	Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. ( Diani, A; Messina, JL; Murray, FT; Sangani, GA; Wachowski, MB; Weinstock, RS, 1997)
"Both exenatide and glibenclamide gave a similar improvement of glycemic control, but only exenatide gave improvements of insulin resistance and beta-cell function, giving also a decrease of body weight and of inflammatory state."	5.14	Exenatide versus glibenclamide in patients with diabetes. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010)
" Changes in A1C, fasting plasma glucose, fructosamine, serum lipids, body weight, and 2-h postprandial glucose after a standardized meal were assessed after 16 wk of treatment."	5.10	Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. ( Bruce, S; Dandona, P; Donovan, DS; Garber, AJ; Park, JS, 2003)
"Our study compared the effects of glimepiride or glibenclamide treatment on body weight over 12 months of treatment in patients with Type 2 diabetes in routine outpatient practice."	5.10	Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. ( Beuth, J; Kolb, H; Martin, S; Scherbaum, WA; Schneider, B; van Leendert, R, 2003)
"The purpose of this study was to compare glycemic control and hypoglycemia rates with Mix75/25 versus glyburide, and with preprandial versus postprandial Mix75/25, in patients aged 60 to 80 years with type 2 diabetes mellitus and persistent hyperglycemia on sulfonylurea therapy."	5.10	Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. ( Erickson, P; Fövènyi, J; Grzywa, M; Herz, M; Milicevic, Z; Pelikanova, T; Sun, B, 2002)
" Body weight, fasting plasma glucose, HbA(1c), blood lactate, total cholesterol and HDL-cholesterol, and triglycerides were measured at the beginning and end of T1 and T5, and end of T2, T3, T6 and T7; postprandial plasma glucose, fasting and postprandial plasma insulin and C-peptide were evaluated at the beginning of T1 and T5, and end of T3 and T7."	5.09	A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. ( Coppini, A; Erle, G; Lora, L; Lovise, S; Marchetti, P; Merante, D; Stocchiero, C, 1999)
" Group I acted as the control, whereas groups II, III, IV, and V were considered experimental groups which received a single dosage (150 mg/kg body weight) of alloxan (ALX) intraperitoneally (i."	4.12	Co-administration of ( Kar, A; Panda, S; Sharma, N; Yadav, D, 2022)
"Two-stage rat hepatocarcinogenesis model was used to induce early carcinogenesis in which thioacetamide (TAA) promotes diethylnitrosamine (DEN) initiated carcinogenesis."	3.96	Diethylnitrosamine and thioacetamide-induced hepatic damage and early carcinogenesis in rats: Role of Nrf2 activator dimethyl fumarate and NLRP3 inhibitor glibenclamide. ( Dwivedi, DK; Jena, GB, 2020)
" FRAE also showed significant increase in serum insulin, body weight and glycogen content in liver and skeletal muscle of STZ-induced diabetic rats while there was significant reduction in the levels of serum triglyceride and total cholesterol."	3.76	Antidiabetic effect of Ficus religiosa extract in streptozotocin-induced diabetic rats. ( Jagtap, A; Pandit, R; Phadke, A, 2010)
" The body weight changes, blood and urine glucose level changes were monitored with changes on the pancreas weight, and after sacrifice, the histopathological changes of pancreas and the changes of insulin- and glucagon-producing cells were also observed by immunohistochemistry."	3.73	Anti-diabetic activity of SMK001, a poly herbal formula in streptozotocin induced diabetic rats: therapeutic study. ( Choi, HS; Choi, HY; Kang, SM; Kim, JD; Ku, SK; Seo, BI, 2006)
"A retrospective analysis was conducted to determine the effects of metformin on glycosylated hemoglobin (HbA1c), body weight, and adverse events in an African-American population."	3.69	A retrospective analysis of the efficacy and safety of metformin in the African-American patient. ( Anderson, D; Briscoe, TA; Cooper, GS; Usifo, OS, 1997)
"To examine the status of ATP-sensitive K+ (K+ATP) channels and 1,4-dihydropyridine-sensitive Ca2+ (Ca2+DHP) channels during experimental cardiac failure, we have measured the radioligand binding properties of [3H]glyburide and [3H]PN 200 110, respectively, in tissue homogenates from the rat cardiac left ventricle, right ventricle, and brain 4 wk after myocardial infarction induced by left coronary artery ligation."	3.68	Regulation of K+ and Ca2+ channels in experimental cardiac failure. ( Bauer, JA; Fung, HL; Gopalakrishnan, M; Kwon, YW; Rutledge, A; Triggle, DJ, 1991)
"To compare pioglitazone or glibenclamide alone and in combination with rosuvastatin on hepatic steatosis in type 2 diabetic patients."	2.78	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. ( D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Perrone, T, 2013)
" The dosage of acarbose and glibenclamide was 50 mg TID and 2."	2.76	Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. ( Lee, IT; Lee, WJ; Lin, SD; Lin, SY; Sheu, WH; Su, SL; Tseng, YH; Tu, ST; Wang, JS, 2011)
"Pioglitazone was better than glibenclamide in decreasing HbA (1c), FPG, FPI, lipid profile, and in improving inflammatory parameters such as Hs-CRP, and ADN."	2.76	Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. ( Bianchi, L; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P, 2011)
"Liraglutide is a once-daily human glucagon-like peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes mellitus (T2DM)."	2.75	Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. ( Kaku, K; Nishida, T; Rasmussen, MF; Seino, Y, 2010)
"In patients with type 2 diabetes inadequately controlled by glyburide monotherapy, the addition of alogliptin resulted in clinically significant reductions in HbA1c without increased incidence of hypoglycaemia."	2.74	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. ( Fleck, PR; Kipnes, MS; Mekki, Q; Pratley, RE; Wilson, C, 2009)
" Glibenclamide dosage increased from 2."	2.73	Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. ( Alvarsson, M; Berntorp, K; Fernqvist-Forbes, E; Grill, V; Holberg, MA; Kirksaether, N; Lager, I; Orn, T; Steen, L; Sundkvist, G, 2008)
"No weight gain was observed in patients treated with nateglinide."	2.72	Nateglinide with glibenclamide examination using the respiratory quotient (RQ). ( Harada, S; Ito, S; Nakaya, Y; Nomura, M, 2006)
"To evaluate the efficacy and safety of two dosage strengths of a single-tablet metformin-glibenclamide (glyburide) combination, compared with the respective monotherapies, in patients with Type 2 diabetes mellitus (DM) inadequately controlled by metformin monotherapy."	2.70	Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. ( Allavoine, T; Howlett, H; Lehert, P; Marre, M, 2002)
"Therefore, glibenclamide treatment of Type 2 diabetes mellitus may have hazardous cardiovascular effects when used under conditions of ischaemia."	2.70	Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. ( Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ, 2002)
" It is thus appropriate to consider dosing it less frequently."	2.69	Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus. ( Ismail, RB; Mafauzy, M; Tun Fizi, A; Wan Mohamad, WB, 2000)
"Ten men with Type 1 diabetes mellitus participated in a randomized, double-blind, crossover, clinical trial with three treatment regimens, namely (1) insulin alone, (2) insulin and placebo, (3) insulin and glibenclamide, each lasting 3 months."	2.68	More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity. ( Birkenholz, M; Kabadi, M; Kabadi, UM; McCoy, S, 1995)
"Eighty NIDDM patients were randomized to treatment with either three preprandial doses of regular insulin (daytime group D) or a bedtime dose of NPH insulin (nocturnal insulinization, group N), both regimens being combined with 10."	2.68	Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. ( Adamson, U; Arner, P; Bolinder, J; Landstedt-Hallin, L; Lins, PE, 1995)
" The first three dose levels comprised increasing single-drug therapy (M or G) or primary combination at increasing but low dosage (MGL), and the second three levels were composed of various high-dose combinations, i."	2.67	Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. ( Bitzén, PO; Hermann, LS; Kjellström, T; Lindgärde, F; Melander, A; Scherstén, B, 1994)
"Twenty-two NIDDM patients completed an open randomized cross-over study comparing metformin and glibenclamide over 1 year."	2.67	Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. ( Hermann, LS; Karlsson, JE; Sjöstrand, A, 1991)
"Insulin sensitivity was increased by glibenclamide but not by glipizide."	2.66	Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. ( Fyhrqvist, F; Groop, L; Groop, PH; Melander, A; Tolppanen, EM; Tötterman, KJ; Wåhlin-Boll, E, 1985)
"Although body weight was unchanged during sulfonylurea/metformin therapy, lean body mass and energy expenditure decreased significantly (p less than 0."	2.66	Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. ( Ekstrand, A; Eriksson, J; Franssila-Kallunki, A; Groop, L; Saloranta, C; Schalin, C; Widén, E, 1989)
" To determine an optimal glyburide dosage schedule, the effects of glyburide once (every morning) or twice daily and chlorpropamide once daily (every morning) were compared in 18 men with non-insulin-dependent diabetes mellitus in a randomized, double-blind fashion."	2.66	Once-daily use of glyburide. ( Fajardo, F; Ginier, P; Levin, SR; Madan, S, 1985)
" The aim of this work was to evaluate antidiabetic activity in Streptozotocin (STZ)-induced diabetic rats and the antioxidant effects of 3',4'-Di-O-acetyl-cis-khellactone (DOAcK), as well as its toxic potential."	1.43	Antidiabetic effect, antioxidant activity, and toxicity of 3',4'-Di-O-acetyl-cis-khellactone in Streptozotocin-induced diabetic rats. ( Burgueño-Tapia, E; Cornejo-Garrido, J; Domínguez-Mendoza, EA; Ordaz-Pichardo, C, 2016)
"05) reduced hyperglycemia, glibenclamide or metformin combined with honey produced significantly much lower blood glucose (8."	1.37	Glibenclamide or metformin combined with honey improves glycemic control in streptozotocin-induced diabetic rats. ( Erejuwa, OO; Gurtu, S; Salleh, MS; Sirajudeen, KN; Sulaiman, SA; Wahab, MS, 2011)
" Chronic administration of the extract resulted in a significant dose dependent reduction in the blood glucose level (P<0."	1.37	Evaluation of the anti-diabetic properties of Mucuna pruriens seed extract. ( Majekodunmi, SO; Odeku, OA; Oyagbemi, AA; Umukoro, S, 2011)
"Glyburide treatment of diabetic rats for 4 weeks corrected the changes observed in diabetic heart."	1.32	The effects of the sulfonylurea glyburide on glutathione peroxidase, superoxide dismutase and catalase activities in the heart tissue of streptozotocin-induced diabetic rat. ( Altan, N; Bilgihan, A; Buğdayci, G; Bukan, N; Kosova, F; Sancak, B, 2004)
"More importantly, the incidence of ventricular tachycardia in the STZ-GLIB group was significantly higher than that in the STZ-VEH group (93% vs 54%, P < 0."	1.32	Long-term treatment with glibenclamide increases susceptibility of streptozotocin-induced diabetic rat heart to reperfusion-induced ventricular tachycardia. ( Iwao, T; Ooie, T; Saikawa, T; Sakata, T; Takahashi, N; Yoshimatsu, H, 2003)
"Glyburide did not increase basal or insulin-stimulated DNA synthesis."	1.30	Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. ( Diani, A; Messina, JL; Murray, FT; Sangani, GA; Wachowski, MB; Weinstock, RS, 1997)
"These included the duration of type 2 diabetes, the presence of other medical conditions, medication history, presence of any contraindications to the use of metformin or sulphonylureas, biochemical measures of diabetic control, and the presence of any diabetic complications."	1.30	Review of management of type 2 diabetes mellitus. ( Greenaway, TM; Peterson, GM; Randall, CT; Vial, JH; Yap, WS, 1998)
"Hypoglycemia was defined as blood glucose (BG) concentration < 60 mg/dl."	1.30	Prospective multicenter study of sulfonylurea ingestion in children. ( Anderson, BD; Anderson, DL; Fenn, J; Gorman, SE; Krenzelok, EP; Muir, SJ; Rodgers, GC; Rose, SR; Spiller, HA; Villalobos, D, 1997)
" In SHR cells, the maximal slope conductance of the levcromakalim-evoked current, normalized by cell capacitance, was decreased, and the dose-response curve was shifted to the right compared with WKY cells."	1.29	Impaired action of levcromakalim on ATP-sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats. ( Abe, I; Fujii, K; Fujishima, M; Nagao, T; Ohya, Y; Setoguchi, M, 1996)
"A total of 40 NIDDM patients were examined (24 females and 16 males) with a mean age of 55."	1.29	[Comparison of two treatment models in type-II diabetic patients with poor metabolic control: Preformed combination of glibenclamide 2,5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? An evaluation at six months]. ( Cavallo, P; D'Argenzio, R; Merante, D; Morelli, A, 1996)
"Glyburide treatment of diabetic rats for 4 weeks corrected the changes observed in diabetic liver."	1.29	Effect of the sulfonylurea glyburide on superoxide dismutase activity in alloxan-induced diabetic rat hepatocytes. ( Altan, N; Engin, A; Hasanoğlu, E; Ongun, CO; Sindel, S; Tuncer, C, 1994)
" Because insulin resistance may contribute to spontaneous hypertension in rats, we sought to determine if long-term administration of glyburide (5 mg/kg per day by diet, age 5 weeks to 5 months) would lower blood pressure in male and female stroke-prone spontaneously hypertensive rats."	1.29	Sex-specific effects of an insulin secretagogue in stroke-prone hypertensive rats. ( Johnson, BA; Peuler, JD; Phare, SM; Sowers, JR, 1993)
"6."	1.29	The effects of glyburide and insulin on the cardiac performance in rats with non-insulin-dependent diabetes mellitus. ( Altan, VM; Ozçelkay, AT; Oztürk, Y; Ozüari, A; Yildizoğlu-Ari, N, 1993)
"Twenty non-insulin-dependent diabetic (NIDDM) patients with secondary failure to sulphonylureas were given combined insulin-glibenclamide therapy."	1.28	Combined insulin-glibenclamide therapy of NIDDM patients in primary health care. A follow-up study of its compliance and efficacy and a review of the literature. ( Adamson, U; Lins, PE; Liu, D; Wettergren, M, 1990)
" A wide interindividual variation in chlorpropamide levels was observed and thus, the prediction of drug concentration was difficult from the dosage alone, despite a statistically significant correlation between the dose per body weight and the serum drug level."	1.26	Chlorpropamide and glibenclamide serum concentrations in hospitalized patients. ( Huupponen, R; Saarimaa, H; Viikari, J, 1982)
" After changing from the sulfonyl ureas glibornuride, glisoxepide or gliquidone the same mean daily dosage of 1."	1.26	[Treatment of adult diabetes with semi-euglucon (author's transl)]. ( Molck, H; Schäfer, D, 1979)
" The changes in weight were similar and both drugs were devoid of serious toxic effects in the dosage prescribed."	1.26	Comparative study of glibenclamide & chlorpropamide in newly diagnosed maturity onset diabetics. ( Haider, Z; Obaidullah, S, 1976)

Research

Studies (164)

Authors

Clinical Trials (10)

Trial Overview

Trial Outcomes

Change From Baseline in Body Weight (Week 12).

Timeframe	Studies, this research(%)	All Research%
pre-1990	51 (31.10)	18.7374
1990's	31 (18.90)	18.2507
2000's	44 (26.83)	29.6817
2010's	33 (20.12)	24.3611
2020's	5 (3.05)	2.80

Authors	Studies
Sirasanagandla, S	1
Kasetti, RB	1
Shaik, AN	1
Natava, R	1
Surtineni, VP	1
Cirradur, SR	1
Chippada, A	1
Domínguez-Mendoza, EA	1
Cornejo-Garrido, J	1
Burgueño-Tapia, E	1
Ordaz-Pichardo, C	1
Rahman, S	1
Jan, G	1
Jan, FG	1
Rahim, HU	1
Sharma, N	1
Kar, A	1
Panda, S	1
Yadav, D	1
Dwivedi, DK	1
Jena, GB	1
Lawal, SK	1
Adeniji, AA	1
Sulaiman, SO	1
Akajewole, MM	1
Buhari, MO	1
Osinubi, AA	1
Nazir, N	1
Zahoor, M	1
Ullah, R	1
Ezzeldin, E	1
Mostafa, GAE	1
Wolf, VLW	1
Breder, I	1
de Carvalho, LSF	1
Soares, AAS	1
Cintra, RM	1
Barreto, J	1
Munhoz, DB	1
Kimura-Medorima, ST	1
Nadruz, W	1
Guerra-Júnior, G	1
Quinaglia, T	1
Muscelli, E	1
Sposito, AC	1
Ezejiofor, AN	1
Igweze, ZN	1
Udowelle, NA	1
Orisakwe, OE	1
Stokum, JA	1
Keledjian, K	1
Hayman, E	1
Karimy, JK	1
Pampori, A	1
Imran, Z	1
Woo, SK	1
Gerzanich, V	1
Simard, JM	1
Bansal, S	1
Chopra, K	1
Indumathi, D	1
Sujithra, K	1
Srinivasan, S	1
Vinothkumar, V	1
Maffioli, P	3
Fogari, E	2
D'Angelo, A	3
Perrone, T	1
Derosa, G	3
Poonam, T	1
Prakash, GP	1
Kumar, LV	1
Ramachandran, S	1
Rajasekaran, A	1
Kellerer, M	1
Pandey, AK	2
Gupta, PP	2
Lal, VK	2
Khan, SS	1
Najam, R	1
Anser, H	1
Riaz, B	1
Alam, N	1
Roche, C	1
Guerrot, D	1
Harouki, N	1
Duflot, T	1
Besnier, M	1
Rémy-Jouet, I	1
Renet, S	1
Dumesnil, A	1
Lejeune, A	1
Morisseau, C	1
Richard, V	1
Bellien, J	1
Ahmed, LA	1
El-Maraghy, SA	1
Rizk, SM	1
Marques, CD	1
Diego, LA	1
Marcondes-Machado, J	1
Amorim, RL	1
Carvalho, LR	1
Módolo, NS	1
Braz, LG	1
Castiglia, YM	1
Franco, CCS	1
Prates, KV	1
Previate, C	1
Moraes, AMP	1
Matiusso, CCI	1
Miranda, RA	1
de Oliveira, JC	1
Tófolo, LP	1
Martins, IP	1
Barella, LF	1
Ribeiro, TA	1
Malta, A	1
Pavanello, A	1
Francisco, FA	1
Gomes, RM	1
Alves, VS	1
Moreira, VM	1
Rigo, KP	1
Almeida, DL	1
de Sant Anna, JR	1
Prado, MAAC	1
Mathias, PCF	1
Ye, Y	1
Lin, Y	1
Perez-Polo, JR	1
Birnbaum, Y	1
Pratley, RE	1
Kipnes, MS	1
Fleck, PR	1
Wilson, C	1
Mekki, Q	1
Yousif, MH	1
Benter, IF	1
Roman, RJ	1
Zhang, W	1
Zhao, J	1
Wang, J	1
Pang, X	1
Zhuang, X	1
Zhu, X	1
Qu, W	1
Ramkumar, KM	2
Ponmanickam, P	1
Velayuthaprabhu, S	1
Archunan, G	1
Rajaguru, P	1
Pareek, H	1
Sharma, S	1
Khajja, BS	1
Jain, K	1
Jain, GC	1
Ghasemi, M	1
Shafaroodi, H	1
Karimollah, AR	1
Gholipour, T	1
Nezami, BG	1
Ebrahimi, F	1
Dehpour, AR	1
Pandit, R	1
Phadke, A	1
Jagtap, A	1
Salvadeo, SA	1
Ferrari, I	1
Ragonesi, PD	1
Querci, F	1
Franzetti, IG	1
Gadaleta, G	1
Ciccarelli, L	1
Piccinni, MN	1
Cicero, AF	2
Seino, Y	1
Rasmussen, MF	1
Nishida, T	1
Kaku, K	1
Harini, R	1
Pugalendi, KV	2
Chen, B	1
Moore, A	1
Escobedo, LV	1
Koletsky, MS	1
Hou, D	1
Koletsky, RJ	1
Ernsberger, P	1
Erejuwa, OO	1
Sulaiman, SA	1
Wahab, MS	1
Sirajudeen, KN	1
Salleh, MS	1
Gurtu, S	1
Bianchi, L	1
Majekodunmi, SO	1
Oyagbemi, AA	1
Umukoro, S	1
Odeku, OA	1
Wang, JS	1
Lin, SD	1
Lee, WJ	1
Su, SL	1
Lee, IT	1
Tu, ST	1
Tseng, YH	1
Lin, SY	1
Sheu, WH	1
Boudjelal, A	1
Henchiri, C	1
Siracusa, L	1
Sari, M	1
Ruberto, G	1
Gao, L	1
Guan, Y	1
Cui, F	1
Liu, YX	1
Zhou, ZN	1
Zhang, Y	1
Pridjian, G	1
Balasubramanian, T	1
Lal, MS	1
Sarkar, M	1
Chatterjee, TK	1
Akbar, DH	1
Hagras, MM	1
Amin, HA	1
Khorshid, OA	1
Marre, M	1
Howlett, H	1
Lehert, P	1
Allavoine, T	1
Sanada, S	1
Node, K	1
Asanuma, H	1
Ogita, H	1
Takashima, S	1
Minamino, T	1
Asakura, M	1
Liao, Y	1
Ogai, A	1
Kim, J	1
Hori, M	1
Kitakaze, M	1
Garber, AJ	3
Bruce, S	3
Fiedorek, FT	1
Omori, Y	1
Fischer, S	1
Patzak, A	1
Rietzsch, H	1
Schwanebeck, U	1
Köhler, C	1
Wildbrett, J	1
Fuecker, K	1
Temelkova-Kurktschiev, T	1
Hanefeld, M	1
Kumari, K	1
Augusti, KT	4
Alvarsson, M	2
Sundkvist, G	2
Lager, I	2
Henricsson, M	1
Berntorp, K	2
Fernqvist-Forbes, E	2
Steen, L	2
Westermark, G	1
Westermark, P	1
Orn, T	2
Grill, V	2
Nagappa, AN	1
Thakurdesai, PA	1
Venkat Rao, N	1
Singh, J	1
Virdi, J	1
Sivakami, S	1
Shahani, S	1
Suthar, AC	1
Banavalikar, MM	1
Biyani, MK	1
Donovan, DS	1
Dandona, P	1
Park, JS	1
Ananthan, R	1
Baskar, C	1
NarmathaBai, V	1
Pari, L	1
Latha, M	1
Martin, S	2
Kolb, H	1
Beuth, J	1
van Leendert, R	1
Schneider, B	1
Scherbaum, WA	1
Takahashi, N	1
Ooie, T	1
Saikawa, T	1
Iwao, T	1
Yoshimatsu, H	1
Sakata, T	1
Elmalí, E	2
Altan, N	5
Bukan, N	2
Sancak, B	1
Bilgihan, A	1
Kosova, F	1
Buğdayci, G	1
Davidson, JA	1
Scheen, AJ	1
Howlett, HC	1
Shinmura, K	1
Tamaki, K	1
Bolli, R	1
Galic, E	1
Vrtovec, M	1
Bozikov, V	1
Schwarzenhofer, M	1
Milicevic, Z	2
Rajasekaran, S	1
Sivagnanam, K	1
Subramanian, S	2
Kvapil, M	1
Swatko, A	1
Hilberg, C	1
Shestakova, M	1
Garber, A	1
Klein, E	1
Sankoh, S	1
Mohideen, P	1
Kim, JD	1
Kang, SM	1
Seo, BI	1
Choi, HY	1
Choi, HS	1
Ku, SK	1
Santhakumari, P	1
Prakasam, A	1
Odetola, AA	1
Akinloye, O	1
Egunjobi, C	1
Adekunle, WA	1
Ayoola, AO	1
Harada, S	1
Nomura, M	1
Nakaya, Y	1
Ito, S	1
Arulselvan, P	1
Senthilkumar, GP	1
Sathish Kumar, D	1
Zheng, J	1
He, J	1
Ji, B	1
Li, Y	1
Zhang, X	1
Holberg, MA	1
Kirksaether, N	1
Zuurbier, CJ	1
Keijzers, PJ	1
Koeman, A	1
Van Wezel, HB	1
Hollmann, MW	1
Habibuddin, M	1
Daghriri, HA	1
Humaira, T	1
Al Qahtani, MS	1
Hefzi, AA	1
Danby, R	1
Bluff, L	1
Deheny, TP	1
Gibson, WR	1
Klimm, HD	1
Vollmar, J	1
Bräuning, C	1
Matsuda, A	1
Kuzuya, T	1
Sugita, Y	1
Kawashima, K	1
Annamala, PT	2
Sönksen, PH	1
Lowy, C	1
Perkins, JR	1
West, TE	1
Lisch, HJ	1
Sailer, S	1
Billingham, MS	1
Hall, RA	1
Simpson, S	1
Bailey, CJ	1
Ratzmann, KP	1
Witt, S	1
Schulz, B	1
Jahr, D	1
Heinke, P	1
Beinze, E	1
Nguyen Thi, C	1
Vetter, U	2
Fussgänger, RD	2
Heinze, E	1
Ranke, M	1
Manske, E	1
Voigt, KH	1
Huupponen, R	1
Viikari, J	1
Saarimaa, H	1
Landstedt-Hallin, L	1
Adamson, U	2
Arner, P	1
Bolinder, J	1
Lins, PE	2
DeFronzo, RA	1
Goodman, AM	1
Hermann, LS	2
Scherstén, B	1
Bitzén, PO	1
Kjellström, T	1
Lindgärde, F	1
Melander, A	2
Atalay, T	1
Ongun, CO	2
Alagöl, H	1
Maiz, A	1
Arteaga, A	1
Klaassen, J	1
Velasco, N	1
Borkosky, M	1
Jiménez, M	1
Acosta, AM	1
Hasanoğlu, E	1
Engin, A	1
Tuncer, C	1
Sindel, S	1
Riddle, MC	1
Peuler, JD	1
Johnson, BA	1
Phare, SM	1
Sowers, JR	1
Ozüari, A	1
Oztürk, Y	1
Yildizoğlu-Ari, N	1
Ozçelkay, AT	1
Altan, VM	1
Ohya, Y	1
Setoguchi, M	1
Fujii, K	1
Nagao, T	1
Abe, I	1
Fujishima, M	1
Zarzuelo, A	1
Jiménez, I	1
Gámez, MJ	1
Utrilla, P	1
Fernadez, I	1
Torres, MI	1
Osuna, I	1
Clarke, BF	2
Campbell, IW	2
Kabadi, UM	1
McCoy, S	1
Birkenholz, M	1
Kabadi, M	1
Malerbi, DA	1
Paiva, ES	1
Duarte, AL	1
Wajchenberg, BL	1
Birkeland, KI	1
Rishaug, U	1
Hanssen, KF	1
Vaaler, S	1
D'Argenzio, R	1
Cavallo, P	1
Merante, D	2
Morelli, A	1
Yiğit, S	1
Malhatun, E	1
Rota, S	1
Kiliç, N	1
Weinstock, RS	1
Murray, FT	1
Diani, A	1
Sangani, GA	1
Wachowski, MB	1
Messina, JL	1
Spiller, HA	1
Villalobos, D	1
Krenzelok, EP	1
Anderson, BD	1
Gorman, SE	1
Rose, SR	1
Fenn, J	1
Anderson, DL	1
Muir, SJ	1
Rodgers, GC	1
Briscoe, TA	1
Anderson, D	1
Usifo, OS	1
Cooper, GS	1
Levin, BE	1
Dunn-Meynell, AA	1
Yap, WS	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes[NCT00286468]	Phase 3	500 participants (Actual)	Interventional	2006-04-30	Completed
The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes[NCT02694575]		241 participants (Actual)	Observational	2015-03-01	Completed
Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes[NCT00393718]	Phase 3	400 participants (Actual)	Interventional	2006-11-30	Completed
A Multicentre Observational Study to Investigate the Improvement in Glucose FLuctuation of Sufficient Acarbose Therapy on Type 2 Diabetes Patient With High Blood Glucose Fluctuation[NCT03805191]		900 participants (Anticipated)	Observational	2019-01-01	Recruiting
Phase 4 Study Evaluation of the Effects of Acarbose Versus Glibenclamide on Mean Amplitude of Glycemic Excursions and Oxidative Stress in Patients With Type 2 Diabetes Insufficiently Controlled by Metformin[NCT00417729]	Phase 4	51 participants (Actual)	Interventional	2007-01-31	Completed
Prospective Randomized Controlled Trial on the Effect of Gastric Bypass and Biliopancreatic Diversion on Type 2 Diabetes Mellitus in Patients With BMI > 35 vs. Medical Therapy[NCT00888836]		60 participants (Actual)	Interventional	2009-04-30	Completed
Metformin Pharmacology in Human Cancers[NCT03477162]	Early Phase 1	18 participants (Actual)	Interventional	2018-05-15	Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.)
Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2018-07-07	Recruiting
Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445]	Phase 4	77 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821]	Phase 3	168 participants (Actual)	Interventional	2018-07-12	Terminated (stopped due to Manufacturer discontinued the production of study drugs.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The change between Body Weight measured at week 12 and Body Weight measured at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.

Change From Baseline in Body Weight (Week 20).

Intervention	kg (Least Squares Mean)
Placebo	-0.12
Alogliptin 12.5 mg QD	0.58
Alogliptin 25 mg QD	0.40

The change between Body Weight measured at week 20 and Body Weight measured at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.

Change From Baseline in Body Weight (Week 26).

Intervention	kg (Least Squares Mean)
Placebo	-0.30
Alogliptin 12.5 mg QD	0.79
Alogliptin 25 mg QD	0.61

The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.

Change From Baseline in Body Weight (Week 8).

Intervention	kg (Least Squares Mean)
Placebo	-0.20
Alogliptin 12.5 mg QD	0.60
Alogliptin 25 mg QD	0.68

The change between Body Weight measured at week 8 and Body Weight measured at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.

Change From Baseline in C-peptide (Week 12).

Intervention	kg (Least Squares Mean)
Placebo	-0.27
Alogliptin 12.5 mg QD	0.47
Alogliptin 25 mg QD	0.33

The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.

Change From Baseline in C-peptide (Week 16).

Intervention	ng/mL (Least Squares Mean)
Placebo	-0.020
Alogliptin 12.5 mg QD	0.162
Alogliptin 25 mg QD	0.206

The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.

Change From Baseline in C-peptide (Week 20).

Intervention	ng/mL (Least Squares Mean)
Placebo	-0.007
Alogliptin 12.5 mg QD	0.222
Alogliptin 25 mg QD	0.153

The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.

Change From Baseline in C-peptide (Week 26).

Intervention	ng/mL (Least Squares Mean)
Placebo	-0.016
Alogliptin 12.5 mg QD	-0.001
Alogliptin 25 mg QD	0.122

The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.

Change From Baseline in C-peptide (Week 4).

Intervention	ng/mL (Least Squares Mean)
Placebo	-0.215
Alogliptin 12.5 mg QD	-0.140
Alogliptin 25 mg QD	-0.153

The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.

Change From Baseline in C-peptide (Week 8).

Intervention	ng/mL (Least Squares Mean)
Placebo	-0.041
Alogliptin 12.5 mg QD	0.122
Alogliptin 25 mg QD	0.136

The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.

Change From Baseline in Fasting Plasma Glucose (Week 1).

Intervention	ng/mL (Least Squares Mean)
Placebo	-0.176
Alogliptin 12.5 mg QD	0.092
Alogliptin 25 mg QD	0.173

The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 1.

Change From Baseline in Fasting Plasma Glucose (Week 12).

Intervention	mg/dL (Least Squares Mean)
Placebo	0.3
Alogliptin 12.5 mg QD	-11.8
Alogliptin 25 mg QD	-19.0

The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.

Change From Baseline in Fasting Plasma Glucose (Week 16).

Intervention	mg/dL (Least Squares Mean)
Placebo	-3.4
Alogliptin 12.5 mg QD	-13.5
Alogliptin 25 mg QD	-15.0

The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.

Change From Baseline in Fasting Plasma Glucose (Week 2).

Intervention	mg/dL (Least Squares Mean)
Placebo	-7.1
Alogliptin 12.5 mg QD	-9.0
Alogliptin 25 mg QD	-13.0

The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 2.

Change From Baseline in Fasting Plasma Glucose (Week 20).

Intervention	mg/dL (Least Squares Mean)
Placebo	-1.8
Alogliptin 12.5 mg QD	-16.7
Alogliptin 25 mg QD	-21.8

The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.

Change From Baseline in Fasting Plasma Glucose (Week 26).

Intervention	mg/dL (Least Squares Mean)
Placebo	-0.4
Alogliptin 12.5 mg QD	-9.3
Alogliptin 25 mg QD	-13.6

The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.

Change From Baseline in Fasting Plasma Glucose (Week 4).

Intervention	mg/dL (Least Squares Mean)
Placebo	2.2
Alogliptin 12.5 mg QD	-4.7
Alogliptin 25 mg QD	-8.4

The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.

Change From Baseline in Fasting Plasma Glucose (Week 8).

Intervention	mg/dL (Least Squares Mean)
Placebo	-3.7
Alogliptin 12.5 mg QD	-14.6
Alogliptin 25 mg QD	-21.1

The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.

Change From Baseline in Fasting Proinsulin (Week 12).

Intervention	mg/dL (Least Squares Mean)
Placebo	-3.2
Alogliptin 12.5 mg QD	-19.9
Alogliptin 25 mg QD	-18.6

The change between the value of fasting proinsulin collected at week 12 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.

Change From Baseline in Fasting Proinsulin (Week 16).

Intervention	pmol/L (Least Squares Mean)
Placebo	-0.5
Alogliptin 12.5 mg QD	-0.7
Alogliptin 25 mg QD	-0.7

The change between the value of fasting proinsulin collected at week 16 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.

Change From Baseline in Fasting Proinsulin (Week 20).

Intervention	pmol/L (Least Squares Mean)
Placebo	-1.8
Alogliptin 12.5 mg QD	-1.5
Alogliptin 25 mg QD	-1.1

The change between the value of fasting proinsulin collected at week 20 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.

Change From Baseline in Fasting Proinsulin (Week 26).

Intervention	pmol/L (Least Squares Mean)
Placebo	-2.5
Alogliptin 12.5 mg QD	-2.1
Alogliptin 25 mg QD	0.0

The change between the value of fasting proinsulin collected at week 26 or final visit and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.

Change From Baseline in Fasting Proinsulin (Week 4).

Intervention	pmol/L (Least Squares Mean)
Placebo	-2.0
Alogliptin 12.5 mg QD	-3.9
Alogliptin 25 mg QD	-2.1

The change between the value of fasting proinsulin collected at week 4 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.

Change From Baseline in Fasting Proinsulin (Week 8).

Intervention	pmol/L (Least Squares Mean)
Placebo	-3.0
Alogliptin 12.5 mg QD	-2.6
Alogliptin 25 mg QD	0.7

The change between the value of fasting proinsulin collected at week 8 and fasting proinsulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.

Intervention	pmol/L (Least Squares Mean)
Placebo	-4.2
Alogliptin 12.5 mg QD	-4.5
Alogliptin 25 mg QD	-0.9

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.

Change From Baseline in Glycosylated Hemoglobin (Week 12).

Intervention	mg/dL (Least Squares Mean)
Placebo	0.01
Alogliptin 12.5 mg QD	-0.38
Alogliptin 25 mg QD	-0.52

The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.

Change From Baseline in Glycosylated Hemoglobin (Week 16).

Intervention	mg/dL (Least Squares Mean)
Placebo	-0.17
Alogliptin 12.5 mg QD	-0.58
Alogliptin 25 mg QD	-0.69

The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.

Change From Baseline in Glycosylated Hemoglobin (Week 20).

Intervention	mg/dL (Least Squares Mean)
Placebo	-0.16
Alogliptin 12.5 mg QD	-0.53
Alogliptin 25 mg QD	-0.66

The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.

Change From Baseline in Glycosylated Hemoglobin (Week 4).

Intervention	mg/dL (Least Squares Mean)
Placebo	-0.08
Alogliptin 12.5 mg QD	-0.43
Alogliptin 25 mg QD	-0.60

The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.

Change From Baseline in Glycosylated Hemoglobin (Week 8).

Intervention	mg/dL (Least Squares Mean)
Placebo	-0.18
Alogliptin 12.5 mg QD	-0.40
Alogliptin 25 mg QD	-0.46

The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.

Change From Baseline in Insulin (Week 12).

Intervention	mg/dL (Least Squares Mean)
Placebo	-0.18
Alogliptin 12.5 mg QD	-0.57
Alogliptin 25 mg QD	-0.65

The change between the value of insulin collected at week 12 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.

Change From Baseline in Insulin (Week 16).

Intervention	mcIU/mL (Least Squares Mean)
Placebo	-0.02
Alogliptin 12.5 mg QD	1.33
Alogliptin 25 mg QD	1.00

The change between the value of insulin collected at week 16 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.

Change From Baseline in Insulin (Week 20).

Intervention	mcIU/mL (Least Squares Mean)
Placebo	-1.21
Alogliptin 12.5 mg QD	1.74
Alogliptin 25 mg QD	0.51

The change between the value of insulin collected at week 20 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.

Change From Baseline in Insulin (Week 26).

Intervention	mcIU/mL (Least Squares Mean)
Placebo	-0.07
Alogliptin 12.5 mg QD	1.18
Alogliptin 25 mg QD	0.93

The change between the value of insulin collected at week 26 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.

Change From Baseline in Insulin (Week 4).

Intervention	mcIU/mL (Least Squares Mean)
Placebo	-1.89
Alogliptin 12.5 mg QD	-0.85
Alogliptin 25 mg QD	0.14

The change between the value of insulin collected at week 4 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.

Change From Baseline in Insulin (Week 8).

Intervention	mcIU/mL (Least Squares Mean)
Placebo	-0.62
Alogliptin 12.5 mg QD	0.64
Alogliptin 25 mg QD	0.89

The change between the value of insulin collected at week 8 and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.

Change From Baseline in Proinsulin/Insulin Ratio (Week 12).

Intervention	mcIU/mL (Least Squares Mean)
Placebo	-0.81
Alogliptin 12.5 mg QD	-0.62
Alogliptin 25 mg QD	0.38

The change between the ratio value of proinsulin and insulin collected at week 12 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 12.

Change From Baseline in Proinsulin/Insulin Ratio (Week 16).

Intervention	ratio (Least Squares Mean)
Placebo	-0.002
Alogliptin 12.5 mg QD	-0.030
Alogliptin 25 mg QD	-0.040

The change between the ratio value of proinsulin and insulin collected at week 16 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 16.

Change From Baseline in Proinsulin/Insulin Ratio (Week 20).

Intervention	ratio (Least Squares Mean)
Placebo	0.003
Alogliptin 12.5 mg QD	-0.037
Alogliptin 25 mg QD	-0.041

The change between the ratio value of proinsulin and insulin collected at week 20 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 20.

Change From Baseline in Proinsulin/Insulin Ratio (Week 26).

Intervention	ratio (Least Squares Mean)
Placebo	-0.005
Alogliptin 12.5 mg QD	-0.035
Alogliptin 25 mg QD	-0.036

The change between the ratio value of proinsulin and insulin collected at week 26 or final visit and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 26.

Change From Baseline in Proinsulin/Insulin Ratio (Week 4).

Intervention	ratio (Least Squares Mean)
Placebo	-0.008
Alogliptin 12.5 mg QD	-0.034
Alogliptin 25 mg QD	-0.034

The change between the ratio value of proinsulin and insulin collected at week 4 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 4.

Change From Baseline in Proinsulin/Insulin Ratio (Week 8).

Intervention	ratio (Least Squares Mean)
Placebo	-0.008
Alogliptin 12.5 mg QD	-0.064
Alogliptin 25 mg QD	-0.043

The change between the ratio value of proinsulin and insulin collected at week 8 and the ratio value of proinsulin and insulin collected at baseline. (NCT00286468)
Timeframe: Baseline and Week 8.

Number of Participants Requiring Rescue.

Intervention	ratio (Least Squares Mean)
Placebo	-0.009
Alogliptin 12.5 mg QD	-0.052
Alogliptin 25 mg QD	-0.045

The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study. (NCT00286468)
Timeframe: 26 Weeks.

Number of Participants With Glycosylated Hemoglobin ≤ 6.5%.

Intervention	participants (Number)
Placebo	28
Alogliptin 12.5 mg QD	30
Alogliptin 25 mg QD	31

The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.

Number of Participants With Glycosylated Hemoglobin ≤ 7.0%.

Intervention	participants (Number)
Placebo	7
Alogliptin 12.5 mg QD	19
Alogliptin 25 mg QD	28

The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.0% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.

Number of Participants With Glycosylated Hemoglobin ≤ 7.5%.

Intervention	participants (Number)
Placebo	18
Alogliptin 12.5 mg QD	60
Alogliptin 25 mg QD	69

The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.

Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%.

Intervention	participants (Number)
Placebo	33
Alogliptin 12.5 mg QD	94
Alogliptin 25 mg QD	112

The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.

Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%.

The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.

Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%.

The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.

Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%.

The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study. (NCT00286468)
Timeframe: Baseline and Week 26.

Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL).

The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study. (NCT00286468)
Timeframe: 26 Weeks.

Body Weight After 24 Weeks of Treatment

Body Weight After 52 Weeks of Treatment

Fasting Plasma Glucose After 24 Weeks of Treatment

Fasting Plasma Glucose After 52 Weeks of Treatment

Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment

Glycosylated Haemoglobin A1c (HbA1c) After 52 Weeks of Treatment

Mean PG in 7-point Plasma Glucose Profile After 24 Weeks of Treatment

Plasma glucose (PG) profile measured after 24 weeks of treatment. The time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. (NCT00393718)
Timeframe: after 24 weeks of treatment

Mean PG in 7-point Plasma Glucose Profile After 52 Weeks of Treatment

Mean plasma glucose(PG) in 7-point plasma glucose profile measured after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. (NCT00393718)
Timeframe: after 52 weeks of treatment

Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 24 Weeks of Treatment

Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 24 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. (NCT00393718)
Timeframe: after 24 weeks of treatment

Mean Postprandial PG Increment in 7-point Plasma Glucose Profile After 52 Weeks of Treatment

Mean postprandial plasma glucose (PG) increment in 7-point plasma glucose profile, ie the mean of the difference of plasma glucose measured before and after a meal, after 52 weeks of treatment. The 7 time points during the day were: Before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, and at bedtime. (NCT00393718)
Timeframe: after 52 weeks of treatment

Postprandial Glucose AUC After 24 Weeks of Treatment

Postprandial glucose AUC measured 0-3 hours after a meal after 24 weeks of treatment (NCT00393718)
Timeframe: after 24 weeks of treatment

Postprandial Glucose AUC After 52 Weeks of Treatment

Postprandial glucose AUC measured 0-3 hours after a meal after 52 weeks of treatment (NCT00393718)
Timeframe: after 52 weeks of treatment

Hypoglycaemic Episodes

Hypoglycaemic episodes measured over 52 weeks of treatment. Hypoglycaemic episodes were defined as major, minor, or symptoms only. Major if the subject was unable to treat her/himself. Minor if subject was able to treat her/himself and plasma glucose was below 3.1 mmol/L. Symptoms only if subject was able to treat her/himself and with no plasma glucose measurement or plasma glucose higher than or equal to 3.1 mmol/L. (NCT00393718)
Timeframe: over 52 weeks of treatment

Concentration of Metformin in Adipose Tissue

To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Plasma.

To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Tumor-adjacent Normal Tissue

To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery

Concentration of Metformin in Whole Blood.

To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery

Lung Tumor Tissue Concentration of Metformin

To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery

Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and Metformin

Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug

Comparison of Changes in Fasting Serum Insulin (FSI)With Pioglitazone and Metformin

Comparison of Changes in Glycosylated Hemoglobin (HbA1c)With Pioglitazone and Metformin

Comparison of Changes in HOMA Percent B and HOMA Percent S With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug

Comparison of Changes in Insulin Levels (HOMA IR,QUICKI) With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug

Comparison of Changes in Lipid Profiles With Pioglitazone and Metformin

"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug

Intervention	number of events per year of exposure (Number)
	All hypoglycaemic episodes	Major	Minor	Symptoms only
Glibenclamide	3.843	0.000	1.103	2.740
Liraglutide	0.694	0.000	0.187	0.507

Intervention	mmol/l (Mean)
	Baseline FSG	3rd Month FSG
Metformin ( 002 Group)	6.2	6.5
Pioglitazone (001 Group)	6.9	5.4

Intervention	μU/ml (Mean)
	Baseline FSI	3rd month FSI
Metformin ( 002 Group)	13.0	13.9
Pioglitazone (001 Group)	16.2	12.3

Intervention	percentage (Mean)
	Baseline HbA1c	3rd month HbA1c
Metformin ( 002 Group)	7.8	7.0
Pioglitazone (001 Group)	7.3	6.7

Intervention	percentage (Mean)
	Baseline HOMA percent beta cells function	3rd month HOMA percent beta cells function	Baseline HOMA percent sensitivity	3rd month HOMA percent sensitivity
Metformin ( 002 Group)	109.3	116.0	76.2	67.2
Pioglitazone (001 Group)	118.9	132.3	51.1	69.3

Intervention	Score on a scale ( SI unit) (Mean)
	Baseline QUICKI	3rd month QUICKI	Baseline HOMA IR	3rd month HOMA IR
Metformin ( 002 Group)	0.57	0.54	3.7	4.3
Pioglitazone (001 Group)	0.52	0.59	5.1	2.9

Intervention	mg/dl (Mean)
	Baseline TC	3rd month TC	Baseline TG	3rd month TG	Baseline HDL	3rd month HDL	Baseline LDL	3rd month LDL
Metformin (002 Group)	193.0	177.0	166.0	175.0	34.4	34.7	125.6	112.0
Pioglitazone (001 Group)	182.0	178	183	195	33	33.2	112.8	105.5

Article	Year
What is new in diabetes?: best articles from the past year. Obstetrics and gynecology, 2012, Volume: 119, Issue:2 Pt 1 Topics: Body Weight; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glyburide;	2012
[Medical management of pregnant women with diabetes]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Blood Glucose; Body Weight; Congenital Abnormalities; Diabetic Nephropathies; Diabetic Retinopathy;	2002
Tolerability profile of metformin/glibenclamide combination tablets (Glucovance): a new treatment for the management of type 2 diabetes mellitus. Drug safety, 2004, Volume: 27, Issue:15 Topics: Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug	2004
[Retrolective study design -- a new tool of evidence-based medicine]. Deutsche medizinische Wochenschrift (1946), 2005, Jul-08, Volume: 130 Suppl 2 Topics: Blood Glucose; Blood Glucose Self-Monitoring; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2	2005
Sulfonylureas in the treatment of diabetes mellitus--1985. Mayo Clinic proceedings, 1985, Volume: 60, Issue:7 Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Comb	1985

Article	Year
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus. Nutrition & diabetes, 2021, 06-12, Volume: 11, Issue:1 Topics: Absorptiometry, Photon; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Body Composition; Body Wei	2021
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:9 Topics: Adipokines; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2	2013
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; D	2009
Exenatide versus glibenclamide in patients with diabetes. Diabetes technology & therapeutics, 2010, Volume: 12, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; C-Reactive	2010
Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. Current medical research and opinion, 2010, Volume: 26, Issue:5 Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Sche	2010
Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2011, Volume: 43, Issue:7 Topics: Administration, Oral; Biomarkers; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; G	2011
Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clinical therapeutics, 2011, Volume: 33, Issue:12 Topics: Acarbose; Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dinoprost;	2011
Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clinical therapeutics, 2011, Volume: 33, Issue:12 Topics: Acarbose; Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dinoprost;	2011
Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clinical therapeutics, 2011, Volume: 33, Issue:12 Topics: Acarbose; Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dinoprost;	2011
Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clinical therapeutics, 2011, Volume: 33, Issue:12 Topics: Acarbose; Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dinoprost;	2011
Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin. Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:8 Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blin	2002
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes, obesity & metabolism, 2003, Volume: 5, Issue:1 Topics: Acarbose; Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Doubl	2003
Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes care, 2003, Volume: 26, Issue:8 Topics: Adult; Aged; Amyloid; Blood Glucose; Body Weight; C-Peptide; Cholesterol, HDL; Diabetes Mellitus, Ty	2003
Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:8 Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combin	2003
Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study. Diabetologia, 2003, Volume: 46, Issue:12 Topics: Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cohort Studies; Diabetes Mellitus, Type 2;	2003
The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. Medical science monitor : international medical journal of experimental and clinical research, 2005, Volume: 11, Issue:12 Topics: Aged; Aged, 80 and over; Biphasic Insulins; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; D	2005
Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:1 Topics: Biphasic Insulins; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedu	2006
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:2 Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combin	2006
Nateglinide with glibenclamide examination using the respiratory quotient (RQ). The journal of medical investigation : JMI, 2006, Volume: 53, Issue:3-4 Topics: Aged; Blood Glucose; Body Weight; Cyclohexanes; Diabetes Mellitus, Type 2; Female; Glyburide; Humans	2006
Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:5 Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration S	2008
Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes care, 1995, Volume: 18, Issue:8 Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. The New England journal of medicine, 1995, Aug-31, Volume: 333, Issue:9 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind	1995
Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes care, 1994, Volume: 17, Issue:10 Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Drug	1994
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ (Clinical research ed.), 1995, Jan-14, Volume: 310, Issue:6972 Topics: Adult; Aged; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type	1995
Different takes on the relationship of insulin treatment to blood pressure. Diabetes care, 1993, Volume: 16, Issue:6 Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gl	1993
More uniform diurnal blood glucose control and a reduction in daily insulin dosage on addition of glibenclamide to insulin in type 1 diabetes mellitus: role of enhanced insulin sensitivity. Diabetic medicine : a journal of the British Diabetic Association, 1995, Volume: 12, Issue:10 Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Circadian Rhythm; Cross-Over Studie	1995
NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia, 1996, Volume: 39, Issue:12 Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glyburide; Glycated Hemoglobin;	1996
A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta diabetologica, 1999, Volume: 36, Issue:1-2 Topics: Blood Glucose; Body Weight; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind M	1999
Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus. Diabetes research and clinical practice, 2000, Volume: 49, Issue:2-3 Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; D	2000
Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. Clinical therapeutics, 2002, Volume: 24, Issue:1 Topics: Aged; Aged, 80 and over; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method;	2002
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients. Diabetic medicine : a journal of the British Diabetic Association, 2002, Volume: 19, Issue:2 Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Pressure; Body Mass Index; Body Weight; C-Pep	2002
Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes. Diabetes care, 2002, Volume: 25, Issue:4 Topics: Abdomen; Adipose Tissue; Adult; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Cholestero	2002
Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes, obesity & metabolism, 2002, Volume: 4, Issue:3 Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; G	2002
Effect of oral hypoglycaemic drugs on glucose tolerance and insulin secretion in borderline diabetic patients. Diabetologia, 1978, Volume: 15, Issue:5 Topics: Administration, Oral; Adult; Biguanides; Blood Glucose; Body Weight; Clinical Trials as Topic; Doubl	1978
Diet and oral antidiabetic drugs and plasma sugar and insulin levels in patients with maturity-onset diabetes mellitus. British medical journal, 1976, Feb-28, Volume: 1, Issue:6008 Topics: Blood Glucose; Body Weight; Female; Glucose Tolerance Test; Glyburide; Humans; Insulin; Male; Middle	1976
Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes care, 1992, Volume: 15, Issue:4 Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Administra	1992
Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles. European journal of clinical pharmacology, 1991, Volume: 41, Issue:3 Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Diabetes Mell	1991
Effects of a gel forming dietary fiber, guar gum, on the absorption of glibenclamide and metabolic control and serum lipids in patients with non-insulin-dependent (type 2) diabetes. International journal of clinical pharmacology, therapy, and toxicology, 1990, Volume: 28, Issue:4 Topics: Adult; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Galactans	1990
Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1989, Volume: 32, Issue:8 Topics: Blood Glucose; Blood Glucose Self-Monitoring; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; D	1989
Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion. Diabete & metabolisme, 1986, Volume: 12, Issue:1 Topics: Blood Glucose; Body Weight; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method;	1986
Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Annals of internal medicine, 1988, Volume: 108, Issue:3 Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gly	1988
Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia, 1988, Volume: 31, Issue:4 Topics: Administration, Oral; Aged; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug C	1988
Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin dependent diabetics poorly controlled with insulin alone. Acta medica Scandinavica, 1985, Volume: 217, Issue:1 Topics: Blood Glucose; Body Weight; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-B	1985
Once-daily use of glyburide. The American journal of medicine, 1985, Sep-20, Volume: 79, Issue:3B Topics: Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus, Type 2; Drug Administration Schedule;	1985
Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Annals of clinical research, 1985, Volume: 17, Issue:3 Topics: Aged; Blood Glucose; Body Weight; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Do	1985
Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics. European journal of clinical pharmacology, 1985, Volume: 28, Issue:6 Topics: Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Erythro	1985
[Blood sugar, serum insulin, nonesterified fatty acids and somatotropin in daily profile in adult diabetics under monotherapy with various sulfonylureas]. Arzneimittel-Forschung, 1974, Volume: 24, Issue:8 Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diet, Diabetic; Fatty Acids, Nonesterified; Glyburide	1974
[Initial results in the treatment of diabetes mellitus with an association of glibenclamide and phenformin]. Minerva medica, 1974, Jan-06, Volume: 65, Issue:1 Topics: Adult; Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus; D	1974
The effect of oral sulphonylureas on blood glucose and insulin. Ghana medical journal, 1973, Volume: 12, Issue:4 Topics: Administration, Oral; Adult; Blood Glucose; Body Height; Body Weight; Clinical Trials as Topic; Fema	1973
[Therapy of diabetes in adults using Glibornurid. Results and clinical studies]. Deutsche medizinische Wochenschrift (1946), 1973, May-04, Volume: 98, Issue:18 Topics: Aged; Blood Glucose; Body Weight; Camphanes; Clinical Trials as Topic; Diabetes Mellitus; Drug Hyper	1973